Avidity Biosciences的库存在一个月内增长了23.7%,其驱动力是罕见疾病的RNA疗法的进展以及分析家的大力支持。 Avidity Biosciences' stock rose 23.7% in a month, driven by progress in RNA therapies for rare diseases and strong analyst support.

Avidity Biosciences(RNA)的库存在一个月内增长了23.7%,去年增长了6.5%,在2025年10月10日以72.6亿美元的市场上限关闭了49.77美元。 Avidity Biosciences (RNA) saw its stock rise 23.7% in one month and 6.5% over the past year, closing at $49.77 on October 10, 2025, with a $7.26 billion market cap. 该公司正在针对肌肉萎缩等罕见疾病开发以RNA为基础的治疗疗法,目前正在进行多个晚期试验。 The company, developing RNA-based therapies for rare diseases like muscular dystrophy, has multiple late-stage trials underway. ClearBridge Investments(ClearBridge Investments)强调这是一项关键控股,指出临床进展强劲,未来增长潜力大。 ClearBridge Investments highlighted it as a key holding, citing strong clinical progress and potential for future growth. 尽管收益和股本回报为负数,但收入猛增88%,分析师保持了一致的“Buy”评级,平均目标为68.11美元,上调为36.8%。 Despite negative earnings and return on equity, revenue surged 88%, and analysts maintain a unanimous "Buy" rating with a $68.11 average target, suggesting a 36.8% upside.